节点文献

低浓度右美托咪定经ERK1/2依赖方式促进TRIO、PKN2和CKAP5介导的骨肉瘤细胞增殖和侵袭

Low-concentration Dexmedetomidine promotes the proliferation and invasion of osteosarcoma cells mediated by TRIO, PKN2 and CKAP5 via ERK1/2-dependent activation

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杨会; 陈磊杰; 赵敏; 王忠慧; 廖珊; 陈帘璞; 龚玲俐; 李珊珊;

【Author】 YANG Hui;CHEN Leijie;ZHAO Min;WANG Zhonghui;LIAO Shan;CHEN Lianpu;GONG Lingli;LI Shanshan;Department of Anesthesiology,Peking University Cancer Hospital Yunnan/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University;Department of Orthopedics,The Second Affiliated Hospital of Kunming Medical University;

【通讯作者】 龚玲俐;李珊珊;

【机构】 北京大学肿瘤医院云南医院/云南省肿瘤医院/昆明医科大学第三附属医院麻醉手术科; 昆明医科大学第二附属医院骨科;

【摘要】 目的 探讨右美托咪定(Dex)对骨肉瘤(OS)细胞的影响及其作用机制。方法 通过MTT实验确定Dex、α2-肾上腺素受体(α2-AR)拮抗剂、PKA抑制剂或ERK1/2抑制剂的最佳暴露浓度;从GEPIA数据库提取与OS样本中ERK1/2表达呈正相关且可能介导其促瘤作用的基因,并采用qRT-PCR、Western blot验证其在OS细胞中的表达情况;利用siRNA沉默候选基因后,通过MTT、流式细胞术、Transwell及集落形成实验,评估ERK1/2通路基因在Dex影响OS细胞增殖、凋亡、侵袭与集落形成能力过程中的作用。结果 25 nM Dex是促进OS细胞活力的最佳浓度,ERK1/2抑制剂(Ravoxertinib)可显著拮抗低浓度Dex导致的OS细胞活力增强,而抑制α2-AR或PKA效果较弱。生信分析发现TRIO、PKN2、CKAP5和NEK4与OS中ERK1/2致癌作用高度相关,Western blot显示Ravoxertinib可阻断Dex引起的TRIO、PKN2、CKAP5和NEK4表达上调。沉默TRIO、PKN2或CKAP5能有效抑制Dex诱导的OS细胞活力增强、侵袭能力提升及集落形成增加,同时减弱Dex对细胞凋亡的抑制作用。结论 低浓度Dex通过ERK1/2依赖性方式上调TRIO、PKN2和CKAP5的表达,从而促进OS细胞的恶性生物学潜能。

【Abstract】 Objective To investigate the effect of Dexmedetomidine(Dex) on osteosarcoma(OS)cells and its underlying mechanism.Methods The optimal exposure concentrations of Dex,a2-adrenergic receptor(a2-AR) antagonist,PKA inhibitor,and ERK1/2 inhibitor were determined by MTT assay.Genes positively correlated with ERK1/2 expression in OS samples and potentially mediating its tumor-promoting effect were extracted from the GEPIA database,and their expression levels in OS cells were verified by qRTPCR and Western blot.After silencing candidate genes with siRNA,MTT assay,flow cytometry,Transwell assay,and colony formation assay were performed to evaluate the role of ERK1/2 pathway genes in the processes by which Dex affects OS cell proliferation,apoptosis,invasion,and colony formation ability.Results 25 nM Dex was the optimal concentration for promoting OS cell viability.The ERK1/2 inhibitor(Ravoxertinib) significantly antagonized the enhancement of OS cell viability induced by low-concentration Dex,whereas inhibition of a2-AR or PKA exerted weaker effects.Bioinformatics analysis identified that TRIO,PKN2,CKAP5,and NEK4 were highly associated with the oncogenic function of ERK1/2 in OS.Western blot demonstrated that Ravoxertinib blocked the upregulation of TRIO,PKN2,CKAP5,and NEK4 induced by Dex.Silencing TRIO,PKN2,or CKAP5effectively suppressed Dex-induced increases in OS cell viability,invasion capacity,and colony formation,while attenuating the inhibitory effect of Dex on cell apoptosis.Conclusion Low-concentration Dex upregulates the expression of TRIO,PKN2,and CKAP5 in an ERK1/2-dependent manner,thereby promoting the malignant biological potential of OS cells.

【关键词】 右美托咪定; 骨肉瘤; TRIO; PKN2; CKAP5; ERK1/2通路;
【Key words】 Dexmedetomidine; Osteosarcoma; TRIO; PKN2; CKAP5; ERK1/2 pathway;
【基金】 云南省教育厅科学研究基金项目(2024J0258、2023Y0656);云南省科技厅-昆明医科大学应用基础研究联合专项基金项目(202401AY070001-153);云南省科技厅基础研究计划项目(202501AT070133);云南省省级临床医学中心科研项目(2024YNLCYXZX0550);昆明医科大学第二附属医院院内科技计划项目(2022yk09);云南省高层次卫生健康技术人才项目(H-2024036)
  • 【分类号】R614;R738.1
  • 【下载频次】31
节点文献中: 

本文链接的文献网络图示:

本文的引文网络